HIGHLIGHTS
- who: September and collaborators from the The University of Melbourne, Australia have published the article: Apolipoprotein-A-I for severe COVID-19-induced hyperin ammatory states: A prospective case study, in the Journal: (JOURNAL) of 15/01/2022
- what: The authors aimed to assess the tolerance of ApoA-I supplementation in four critically ill individuals who developed a COVID-19-associated hyperinflammatory state and were included in an ApoA-I compassionate-access program. This study has several limitations including its uncontrolled design and the small size of the cohort which could be included in the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.